Acta Neuropathologica Communications (Nov 2020)

Clinical and mutational profiles of adult medulloblastoma groups

  • Gabriel Chun-Hei Wong,
  • Kay Ka-Wai Li,
  • Wei-Wei Wang,
  • Anthony Pak-Yin Liu,
  • Queenie Junqi Huang,
  • Aden Ka-Yin Chan,
  • Manix Fung-Man Poon,
  • Nellie Yuk-Fei Chung,
  • Queenie Hoi-Wing Wong,
  • Hong Chen,
  • Danny Tat Ming Chan,
  • Xian-Zhi Liu,
  • Ying Mao,
  • Zhen-Yu Zhang,
  • Zhi-Feng Shi,
  • Ho-Keung Ng

DOI
https://doi.org/10.1186/s40478-020-01066-6
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Adult medulloblastomas are clinically and molecularly understudied due to their rarity. We performed molecular grouping, targeted sequencing, and TERT promoter Sanger sequencing on a cohort of 99 adult medulloblastomas. SHH made up 50% of the cohort, whereas Group 3 (13%) was present in comparable proportion to WNT (19%) and Group 4 (18%). In contrast to paediatric medulloblastomas, molecular groups had no prognostic impact in our adult cohort (p = 0.877). Most frequently mutated genes were TERT (including promoter mutations, mutated in 36% cases), chromatin modifiers KMT2D (31%) and KMT2C (30%), TCF4 (31%), PTCH1 (27%) and DDX3X (24%). Adult WNT patients showed enrichment of TP53 mutations (6/15 WNT cases), and 3/6 TP53-mutant WNT tumours were of large cell/anaplastic histology. Adult SHH medulloblastomas had frequent upstream pathway alterations (PTCH1 and SMO mutations) and few downstream alterations (SUFU mutations, MYCN amplifications). TERT promoter mutations were found in 72% of adult SHH patients, and were restricted to this group. Adult Group 3 tumours lacked hallmark MYC amplifications, but had recurrent mutations in KBTBD4 and NOTCH1. Adult Group 4 tumours harboured recurrent mutations in TCF4 and chromatin modifier genes. Overall, amplifications of MYC and MYCN were rare (3%). Since molecular groups were not prognostic, alternative prognostic markers are needed for adult medulloblastoma. KMT2C mutations were frequently found across molecular groups and were associated with poor survival (p = 0.002). Multivariate analysis identified histological type (p = 0.026), metastasis (p = 0.031) and KMT2C mutational status (p = 0.046) as independent prognosticators in our cohort. In summary, we identified distinct clinical and mutational characteristics of adult medulloblastomas that will inform their risk stratification and treatment.

Keywords